null

null

null

null

Net cash position; minimal debt. As of 2024, ~$200M+ cash runway. A 200bps rate rise marginally increases interest income, not expense.

Low sensitivity; no material floating-rate debt. Higher rates modestly boost cash yield on treasury holdings, extending runway slightly.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-source API manufacturers (likely in India/China) for losmapimod and FTX-6058 APIs; geopolitical risk concentrated in Asia-Pacific CMO hubs.

Minimal international revenue; clinical-stage company with no commercial product. Currency devaluation exposure is near zero currently.

Primarily U.S.-domiciled operations. Clinical trials in select EU/global sites but no material foreign revenue; FX exposure negligible.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or dual CMOs for drug substance manufacturing; likely non-substitutable within 12 months without trial delay risk.

Clinical-stage biopharma; not cloud-infrastructure-dependent for core operations. A cloud termination would disrupt IT/data but not clinical outcomes imminently.

Secondary model involves licensing/collaboration revenue (e.g., GSK partnership). Cloud disruption affects analytics platforms, not partnership contractual flows.

Moderate API coupling risk via bioinformatics and genomics platforms; switching CROs or data vendors could cause 6–12 month delays in trial timelines.

Low Howey risk; revenue model is pharmaceutical licensing and grants, not investment contracts. Equity is standard registered common stock.

Very High

Moderate GDPR exposure from EU clinical trial patient data. CCPA applies to U.S. employee/vendor data. Compliance programs standard for clinical-stage biotech.

Low antitrust risk; no market-dominant commercial products. Orphan drug/rare disease focus reduces market concentration scrutiny.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Near-100% non-recurring; revenue is milestone-based collaboration payments (GSK deal) and grants. No subscription revenue stream exists.

Milestone and royalty monetization via GSK collaboration for losmapimod; future royalties contingent on approval. Entirely event-driven, not recurring SaaS.

No commercial pricing architecture yet. Future pricing will likely follow rare disease/orphan drug premium model ($100K–$300K+ annually per patient).

High potential pricing power in rare disease (FSHD, SCD); limited competition and orphan designation support premium pricing upon approval.

Projected gross margins of 80–90%+ upon commercialization, consistent with specialty/rare disease biopharma norms with royalty or direct sales model.

No free-rider leakage problem; clinical-stage company with no consumer product. Collaboration partner (GSK) locked in via contractual milestones.

Revenue growth is not headcount-linear; milestone payments scale with trial success, not team size. Doubling revenue requires minimal incremental headcount.

Sublinear headcount growth relative to revenue milestones. Primary cost driver is clinical trial spend (CRO/CMO), not internal FTEs.

Not applicable; Fulcrum is not a franchise business model.

At 10x scale (commercial launch), CAC analogue is physician/KOL engagement cost in rare disease; patient identification cost estimated $10K–$50K per patient.

No meaningful network effects; biopharma drug development does not exhibit user-growth-driven value compounding.

AI displacement risk low-to-moderate; AI could accelerate target discovery and genomics analysis but cannot replace clinical trial execution or regulatory pathways.

Moderate-to-high recession resistance; rare disease patients have inelastic demand and payer coverage. Clinical funding risk exists if capital markets tighten.

Pharmaceutical partners (GSK) as primary revenue customer; single-partner concentration risk is significant (>90% of collaboration revenue).

Future commercial customers: rare disease patients (FSHD, SCD) via specialty pharmacy/hospital channels. Highly concentrated, small addressable population.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated toward future-state clinical infrastructure (trials, CMC development), not legacy operations. No legacy asset reallocation burden.

0001680581

FULC